Unity Biotechnology Inc
UBX
Market Cap$24.68M
Close$
$-0.49
132.9% downside
Current Fair Value
132.9% downsideOvervalued by 132.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $24.68 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.99 |
| Outstanding Shares | 16,789,577 |
| Avg 30 Day Volume | 47,995 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Unity Biotechnology Inc
70 employees
CEO: Anirvan Ghosh UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.